A treatment for Parkinson’s Disease being developed by Impax Laboratories Inc. did well in a Phase III clinical trial.
The Hayward company (NASDAQ: IPXL) said Monday that the drug, IPX066, an extended release treatment, performed well compared against an immediate release version of the same compound.
No comments:
Post a Comment